Delphia (USA)’s Altimmune ALT Stock Holding History

Delphia (USA)’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-21,205	Closed	-$74.9K	–	13
2023 Q2	$74.9K	Buy	+21,205	New	+$95.2K	0.12%	203
2022 Q3	–	Sell	-19,543	Closed	-$229K	–	287
2022 Q2	$229K	Buy	+19,543	New	+$121K	0.16%	250

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Delphia (USA)'s ALT Position: Q3 2023 in Review

Delphia (USA) sold out of Altimmune (ALT) in Q3 2023, closing a stake of 21,205 shares — an estimated $74.9K sold.

Delphia (USA) first reported a position in ALT in Q2 2022 and held it in 2 quarters. The position peaked at $229K in Q2 2022. 112 funds tracked by Wall St. Rank hold ALT as of Q3 2023.

Delphia (USA) reported no remaining Altimmune position as of Q3 2023 after selling out during the quarter.
Delphia (USA) sold 21,205 Altimmune shares in Q3 2023, an estimated $74.9K.
Delphia (USA) first reported a position in Altimmune in Q2 2022 and held it in 2 quarters.
Delphia (USA)'s Altimmune position peaked at $229K in Q2 2022.
112 funds tracked by Wall St. Rank held Altimmune as of Q3 2023.

Based on Delphia (USA)'s 13F filing for Q3 2023, filed 15 Nov 2023.